Press release
Natera to Present New Data at the 2024 SGO Annual Meeting on Women’s Cancer, Following Recent Medicare Coverage Decisions in Ovarian and Breast Cancers
AUSTIN, Texas--(BUSINESS WIRE)-- Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA testing, today announced new data being presented on its
About this update from Natera, Inc.
[{"type":"text","content":" AUSTIN, Texas--(BUSINESS WIRE)--\nNatera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA testing, today announced new data being presented on its personalized and tumor-informed molecular residual disease (MRD) test, Signatera™, and hereditary cancer test, Empower™, at the 2024 Society of Gynecologic Oncology (SGO) Annual Meeting on Women’s Cancer taking place March 16-18, 2024.\n\n\nA total of seven abstracts will be presented, including two oral presentations and five poster presentations. The presentations will feature new data highlighting Signatera’s predictive and prognostic utility in ovarian cancer and other gynecologic malignancies.\n\n\n“On the heels of receiving Medicare coverage for Signatera in ovarian cancer and for breast cancer in the neoadjuvant setting, we are thrilled to share new Signatera and Empower data with the gynecologic oncology community,” said Adam ElNaggar, MD, medical director of oncology at Natera. “We believe this momentum is indicative of the growing clinical value our tests provide for patients across the continuum of gynecologic cancer care, and demonstrate our continued leadership in MRD.”\n\n\nBelow is the full list of Signatera and Empower data presentations at the SGO Annual Meeting.\n\n\nOral Presentations:\n\n\n\nFocused Plenary I: The Science to Drive Purpose | March 16, 2:15 - 3:30 PM | Presenter: Anne Knisely, MD | Ovarian Cancer\nPrognostic implications of minimal residual disease detection by second look laparoscopy and circulating tumor DNA (ctDNA) in patients with ovarian cancer after frontline therapy\n\n\n\n\nFocused Plenary IV: ctDNA: Molecular Mirrors & Markers | March 17, 1:45 - 2:45 PM | Presenter: Mike Shalamov | Gynecologic Cancers\nUtility of ctDNA as an early predictive biomarker of response to radiation in gynecologic malignancies\n\n\n\nPoster Presentations:\n\n\n\nPoster #1241 | Session 1 | March 17, 1:15 - 2:45 PM | Presenter: Michael Toboni, MD | Ovarian Cancer\nPARPi response monitoring using personalized ctDNA testing in patients with ovarian cancer\n\n\n\n\nPoster #1242 | Session 1 | March 17, 1:15 - 2:45 PM | Presenter: Peter W. Ketch, MD | Uterine Cancer\nTreatment Monitoring Utilizing ctDNA-based MRD Detection in Early Stage Uterine Cancer\n\n\n\n\nPoster #1243 | Session 1 | March 17, 1:15 - 2:45 PM | Presenter: Michael Toboni, MD | Uterine Cancer\nPer...